Finnish health tech company Nightingale Health Oy (“Nightingale”) and Estonian Biobank, population-based biobank of the Institute of Genomics at the University of Tartu (“EBB”) today announced long-term strategic collaboration. The aim of Estonian Biobank is to pioneer a global initiative to empower the entire population of Estonia with modern tools of personalized medicine to realize early disease prevention. The strategic collaboration between Nightingale and Estonian Biobank contributes to this aim.

In the first phase of the collaboration Nightingale’s proprietary blood-testing technology and its health data platform are utilized to provide complementary health insights to the 200,000 EBB participants to detect holistically disease risks and preventative needs of individuals. The EBB cohort reflects quite closely the age, sex and geographical distribution of the Estonian population and can be used to model nationwide programs.

“Nightingale’s belief is that empowering people with better health information enables better decisions on an individual level to prevent diseases,” said Teemu Suna, CEO of Nightingale.

“Bringing health benefits to participants, people and the entire society is the core purpose of biobanking. Bringing modern tools for returning health insights to the biobank participants strongly serves that purpose,” said Prof. Tõnu Esko, Head of Estonian Biobank Innovation Center, University of Tartu.

Nightingale’s proprietary highly accurate blood test is validated by regulatory approvals and by more than 300 peer-reviewed scientific publications. Nightingale operates as a private healthcare provider in Finland.

In addition to bringing novel health insights to the participants, Nightingale biomarker data is also provided to the EBB to advance scientific medical research and for unlocking the impact of human genome variation.

“Running Nightingale blood analysis for all of our biobank samples opens novel scientific opportunities in healthcare and drug discovery. We are also looking forward to replicating our findings with multiple other global biobanks containing Nightingale biomarker data,” said Prof. Esko.

After completing the first phase, the aim is to take Nightingale’s health data platform into use in personal medicine initiatives across the world.

“Together the high scalability and low price point of Nightingale technology can be used to empower nations with better personal health insights, giving everyone better tools to stay healthy and prevent diseases. It’s a privilege to work together with EBB, one of the most innovative biobanks in the world, towards realizing early disease prevention in Estonia,” said Mr. Suna.

“We are very excited to take our globally pioneering initiative forward together with Nightingale and continue our long-term efforts in bringing health benefits for the society through advancements in science and technology,” said Prof. Esko.

More Information:

Teemu Suna

CEO, Founder, Nightingale Health Oy

teemu.suna@nightingalehealth.com

Prof. Tõnu Esko

Head of Estonian Biobank Innovation Center, University of Tartu

tonu.esko@ut.ee


Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks comprehensively, we are creating a world-leading health data platform that enables better preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with better health insights, we accelerate scientific discoveries, industry developments and betters personal health for everyone.